NEVVI Medicare utilization intelligence
or

← back

Provider profile

BIRHIRAY, RUEMU MD

Hematology-Oncology · NPI 1295735058 · INDIANAPOLIS, IN

2
Groups
42
Codes · 2024
70,207
Disclosed services

BIRHIRAY, RUEMU is a Hematology-Oncology in INDIANAPOLIS, IN, a member of 2 medical groups, who billed 42 distinct codes to Medicare Part B in 2024.

Groups: AMERICAN ONCOLOGY PARTNERS PA (FORT WAYNE, IN) · RIVERVIEW HOSPITAL (NOBLESVILLE, IN) — member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

70,207
disclosed services
42
codes billed to Medicare Part B
Prior year · CY2023 86,398 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0185 Injection, aprepitant, 1 mg
J0897 Injection, denosumab, 1 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J2469 Injection, palonosetron hcl, 25 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
96372 Injection of drug or substance under skin or into muscle
J2405 Injection, ondansetron hydrochloride, per 1 mg
96413 Administration of chemotherapy into vein, 1 hour or less
96375 Injection of additional new drug or substance into vein
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J3489 Injection, zoledronic acid, 1 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96417 Administration of additional new drug or substance into vein, 1 hour or less
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J1200 Injection, diphenhydramine hcl, up to 50 mg
81002 Urinalysis, manual test
J7030 Infusion, normal saline solution , 1000 cc
96411 Administration of additional new drug or substance into vein using push technique
99426 Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
96415 Administration of chemotherapy into vein, each additional hour
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J3490 Unclassified drugs
96360 Infusion into a vein for hydration, 31-60 minutes
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96361 Infusion into a vein for hydration, each additional hour
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96374 Injection of drug or substance into vein
38222 Biopsy and aspiration of bone marrow sample for diagnosis
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.